Peers of Spyre Therapeutics Inc (SYRE)
Side-by-side comparison
Health Care · Biotechnology
Enterprise value divided by trailing twelve-month revenue. A capital-structure-neutral sales valuation metric.
Latest EV/Sales
545.69x
As of Jun 28, 2024
Beyond EV/Sales, the valuation view includes forward multiples, EV ratios, cash flow yields, and multi-year chart history for further research.
| Date | EV/Sales |
|---|---|
| Jun 28, 2024 | 545.69x |
| Jun 27, 2024 | 503.22x |
| Jun 26, 2024 | 539.32x |
| Jun 25, 2024 | 523.39x |
| Jun 24, 2024 | 583.91x |
| Jun 21, 2024 | 577.01x |
| Jun 20, 2024 | 658.23x |
| Jun 18, 2024 | 666.72x |
EV/Sales = Enterprise Value / Revenue (TTM). Enterprise Value = Market Cap + Total Debt − (Cash & Short-Term Investments + Long-Term Investments).
EV/Sales is particularly useful in M&A analysis and for companies with significant debt.
Read the general EV/Sales definition, formula, and analyst usage guide.
EV/Sales guideInformational research only; not personalized advice. Values reflect the latest available data on Chartloom and may differ from other sources.
Side-by-side comparison